Objective: to describe aminoglycoside use and nephrotoxicity in patients older than 75 years. Design: retrospective multicenter study. Setting: hospital department, rehabilitation, long-term care center. Population: patients ≥75 years old treated by aminoglycosides. Results: 184 patients, mean age: 84.4 years (range: 75-101). One hundred and twenty-seven patients received other nephrotoxic drug(s). Gentamicin (70%) and amikacin (30%) were used and the once-daily dosing was preferred (92%). Average treatment period was 2.75 (1-10) days for amikacin and 4.4 (1-30) for gentamicin with average dosage 13.5 and 3.5 mg/kg/day, respectively. The monitoring of maximal plasmatic concentration (C max ) was done in 37 patients, 9 of them had probabilistic treatment. Only one had a C max fulfilling the objective of French recommendations (gentamicin >30 mg/l, amikacin >60 mg/l). When infection was documented, the objective of C max >10 × minimal inhibitory concentration of the strain was reached for 27%. Minimal plasmatic concentration was checked in 38% of cases, with adequate value (gentamicin <0.5 mg/l, amikacin <2.5 mg/l) for 37%. At the end of aminoglycoside course, 40 patients increased their serum creatinine >25% of the baseline value. In multivariate analysis, this was associated with treatment length ≥3 days and concomitant use of nephrotoxic drugs. Conclusion: aminoglycosides dosing used in elderly patients probably need therapeutic drug monitoring and dose adjustment. Aminoglycosides are used to treat severe infections. One of the most important side effects is nephrotoxicity in oldest patients. To minimise nephrotoxicity, short treatments are necessary and avoiding others nephrotoxic drugs could be relevant.
Introduction
Aminoglycosides are intravenous bactericidal antibiotics whose broad spectrum encompasses Gram-negative and Grampositive pathogens. They are mainly used in severe infections. They exert their bactericidal effect against Gram-negative bacteria through a concentration-dependent activity, whereas the efficacy determinant against Gram-positive bacteria is mostly the area under the curve over 24 h. Elimination is almost completely through renal clearance [1] . Aging of the population, combined with the frequency of severe infections and increasing bacterial resistance, leads to widespread aminoglycoside use in old patients. However, this population has an increased risk of toxicity such as renal failure [2] . The physiological conditions of old patients also influence pharmacokinetic of aminoglycosides (PK) [2] . Some studies have been performed on PK of aminoglycosides in older patients [3] [4] [5] but only few analysed nephrotoxicity [4, 5] . In 2011, the Agence Française de Sécurite Sanitaire des Produits de Santé and the French Infectious Diseases Society (Société de Pathologie Infectieuse de Langue Française, SPILF) published an update of guidelines on the use of aminoglycosides [6] . The recommendations promote oncedaily use, short treatment and adequate dose, as efficacy requires a plasmatic peak concentration (C max ) as high as 8-to 10-fold the minimum inhibitory concentration (MIC) of the target pathogen, while toxicity is mostly related to high-trough (C min ) concentration [1, 6, 7] . The aim of our study was first to describe aminoglycosides use in current practice in older patients (≥75 years old) and then to analyse nephrotoxicity.
Methods
A national multicenter retrospective observational study was conducted on behalf of the SPILF and of Geriatric Medicine society (Société Française de Gériatrie et Gérontologie, SFGG). The inclusion criteria were patients 75 years and older hospitalised for >24 h who received at least one dose of aminoglycoside, after March 2011 (date of publication of the French national guidelines for aminoglycoside use) and discharged before the beginning of the study. Electronic mailing lists of the two societies were used to recruit the investigator centers. Each participating center had to include the last five consecutive patients fulfilling the inclusion criteria. A standardised data collection sheet were retrospectively filled in from the medical charts including: demographics (sex, age), weight, serum creatinine and glomerular filtration rate (GFR) estimated by the Modification of Diet in Renal Disease (MDRD) formula [8] , concomitant use of other nephrotoxic drugs, type of infection, microbiological data, all antibiotic drugs used, and for aminoglycosides, their plasmatic concentration monitoring, route of administration and length of treatment. Follow-up data, such as survival and renal function, were also evaluated. Physician should report ototoxicity if patient complained of loss of audition or dizziness. However, audiolgic or vestibular investigations were not required. We analysed PK parameters according to values compared with national recommendations [6] : C min of ≤0.5 mg/l for gentamicin and 2.5 mg/l for amikacin and C max of 30-40 mg/l for gentamicin and 60-80 mg/l for amikacin when aminoglycoside were used as empiric treatment (without documentation when C max was checked) and a C max of >10 times the MIC of strain isolated in documented infections.
Nephrotoxicity was defined by an increase of creatinine level over 25% between admission and the last available measure was used to define nephrotoxicity. We used the National Kidney Foundation (NKF) guidelines for chronic kidney diseases classification [9] : renal impairment was considered as patients who had worsened functional class.
Statistical analysis
Descriptive statistics were used to characterise the population. Discrete variables were expressed as counts with percentages and continuous data were expressed as mean ± SD. Categorical data were compared using χ 2 -test or Fisher's exact test, as appropriate, and continuous variables were compared using the Student's t-test. The Mann-Whitney U-test and the Wilcoxon-rank test were used to compare continuous non-normal distributed variables. A logistical regression was used to examine the contribution of factors for renal failure in the univariate analysis. Multivariate logistic regression analysis was carried out for the factors associated with the risk of renal failure by the univariate analysis (P < 0.20). The threshold of significance was set at 5% for all tests and pertinent statistical results were presented in the format of odds ratio (OR) with 95% confidence interval (CI). The risk factors of renal failure was defined by either an increase of 25% of serum creatinine or an increase of 50% or 44 µmol/l of serum creatinine or worsening functional class of chronic renal disease. The concordance of those risk factors was checked by calculating the multi-judge kappa concordance coefficient. It ranges between 0 and 1: the closer to 1 the value, the higher the degree of concordance is. All statistical analyses were performed with SAS software, version 9.0 (SAS Institute, Inc, Cary, NC, USA).
Results
Thirty-eight centers participated among French hospitals and geriatric care centers. There were 15 geriatric medicine units, 12 infectious disease units, 2 rehabilitation centers, 2 long-term care departments, one nursing home and 7 various units such as internal medicine or intensive care units. One hundred and eighty-four patients were included (Table 1) . One hundred and seventy-six (69%) received at least one concomitant potentially nephrotoxic drug: loop diuretic (76 patients), angiotensin converting enzyme inhibitor (ACEi) (38), angiotensin receptor Blocker (28), vancomycin (21), iodine contrast product injection (20) and other drugs (6) . The infection's sites were urinary tract (UT) (60 patients), endocardium (36), lower respiratory tract (LRT) (25), bone and joint (BJ) (15), skin and soft tissues (SST) (6), brain (2). Thirty-one patients had isolated bacteremia, 2 febrile neutropenia and 7 fever of unknown origin (FUO). Infection was documented for 153 patients (83%): 79 had Gram-positive cocci (GPC) isolated, 68 Gram-negative bacilli (GNB) and 6 other. The most frequently isolated bacteria were: Staphylococcus aureus (34 strains), Escherichia coli (31), Streptococcus sp. (21), Enterococcus sp. (18) and P. aeruginosa (16).
Ninety-six patients received a first antibiotic before the aminoglycoside, such as β-lactamin in 71cases, quinolone in 16, macrolide or lincosamide in 8 and cotrimoxazole in 6. The sites of infection were UT (22), endocardium (22), LRT (18), bacteremia (15), BJ (8), FUO (5), SST (3), febrile neutropenia (2) and brain abscess (1) . Four patients received aminoglycoside alone, whereas 138 patients were concomitantly given other antimicrobial and 42 patients 2 or more. The two used aminoglycosides were gentamicin and amikacin (Table 2) . Once-daily administration was used for 169 patients (92%) mostly intravenously. Thirty-seven patients (20%) had a C max measured. Nine patients who received aminoglycosides as empiric treatment had C max checked and only 1 (11%) reached the objective recommended by national guidelines [6] . C max control was used for 28 patients who had documented infection. Only 22 isolated strains had an available MIC. Six out of 22 patients (27%) had a C max of >10 MIC. Median C max value was 8.4 mg/l for gentamicin and 45 mg/l for amikacin. Only 16 patients had a dosage adjustment reported. Patients with plasma C max monitoring had no statistically different age, body mass index, severity of disease or albuminaemia compared with other patients. Twenty-two patients had only one C max dosage, 9 had 2 and 6 had ≥3 monitored C max . C min was monitored in 71 patients (38%). Out of these 71 patients, 26 C min (36%) were correct (<2.5 mg/l for amikacin and <0.5 mg/l for gentamicin) [6] . Eleven out of 45 patients (24%) who had C min above the recommended value had an adaptation of interval length between administrations. No statistical difference was found for unit of admission, albuminaemia, renal function and use of other nephrotoxic drug between patient who had C min monitoring and those who did not. Thirty-five patients had 1 C min dosage, 14 had 2, 10 had 3 and 12 had ≥4 controlled C min (up to 13 × C min dosages). Aminoglycosides were stopped in 47 patients (25%) before the end of treatment such as physician initially prescribed. Twenty-four had a GPC infection, 7 a GNB, 6 a polymicrobian infection and 10 did not have isolated pathogen. Site of infections were: endocardium (16), UT (kidney 6, prostate 3), bacteremia (6), FUO (6), BJ (5), LRT (4), febrile neutropenia (1). discontinuation were: adverse event (n = 13), difficult venous access (n = 4), failure of treatment (n = 2) and not reported (n = 28). At the end of hospitalisation, 117 patients were considered cured and 19 had a remaining infection. Forty-eight patients (26%) died: 11 patients out of 25 (44%) who had LRT infection died, 11 out of 31 (35%) with bacteremia, 12 out of 36 (33%) with endocarditis, 9 out of 60 (15%) with UT infection and 5 among those who had other sites of infection. Death was attributed to infection in 28 cases. No ototoxicity was reported. Forty patients (22%) had an increase in their serum creatinine level over 25% at the end of hospitalisation. In univariate analysis, significant factors associated with increased serum creatinine were (Table 3) 
Discussion
Aminoglycosides are bactericidal antibiotics with a remarkable efficacy and synergistic activity when used in combination regimens for severe infections or resistant bacteria common in the elderly. However, the well-known nephrotoxicity of aminoglycosides limits their use in this frail population. Aminoglycosides have their best bactericidal activity as concentration-dependent antimicrobials against GNB: that is, the drug C max should at least be 8-to 10-fold the pathogen MIC. Based on the latest European Committee Antimicrobial Susceptibility testing [10] , the French recommendations and also some recent data [6, 11, 12] proposed to increase the target concentration for a real therapeutic use of this antimicrobial class. Higher dosages (15-20 mg/kg/day of amikacin, 3-8 mg/kg/day of gentamicin) have therefore been proposed to reach this goal. It is clear that microbiological and clinical susceptibilities do not always match: indeed, even if from a microbiological point of view amikacin is considered as a therapeutic choice up to MIC = 16 mg/l, according to CLSI standards, such a strain would really require amikacin target concentration at 160 mg/l, which becomes an impossible threshold. Our study is one of the first focusing on aminoglycosides practical use in the oldest patients. The French network of the geriatric and infectious disease societies led to a large number of patients included. We decided to include only five consecutive patients per center to limit center bias. Low value of mean serum albumin is an illustration of both intensity of inflammation and also mild-to-moderate malnutrition. Most of the patients had a chronic renal failure with an average GFR of 49 ml/min/1.73 m 2 . Nevertheless, renal impairment could also be due to the sepsis related injury, pre-existing risk factors, dehydration and other nephrotoxic treatments [13] . The high number of patients receiving loop diuretics and ACEi or angiotensin receptor blockers also reflects the burden of comorbidities in the studied population. Concurrent presence of multiple comorbidities and severity of infections could explain the length of stay (24 days) and mortality rate (26%). Few patients received subcutaneous or intramuscular injections. Subcutaneous route is not routinely recommended for aminoglycosides because of the risk of skin necrosis [6, 14] . No such side-effect was reported in our study. Treatment duration was associated with renal impairment and could be reduced in most of cases except endocarditis. Bactericidal and synergic effect of aminoglycosides are the most important at the beginning of the treatment in order to quickly reduce inoculums and withdraw therefore the administration as soon as possible [1, 6] . This can be particularly true for geriatric patients who seem to have significant renal function impairment after 3 days. The single daily dose was associated with less risk of renal impairment in univariate analysis but this was not significant in the multivariate model. The average dose was lower than recommended for amikacin (mean: 13.5 mg/kg/day) and in the lower range for gentamicin (mean: 3.5 mg/kg/day). ratio of ≥8-10 [1, 6, 11] . To achieve the target concentration, a high dose of aminoglycoside should be delivered. The low administered dose recorded in the present study could explain that only few patients reached the targeted C max . It may also be related to treatment failure and infection-related mortality. Indeed, even if the extension in the aminoglycoside administration could afford to obtain therapeutic levels, it is still difficult to accept full single dose in case of renal impairment. As a matter of facts, C max monitoring seems absolutely advisable in the presence of high MIC or difficult-to-treat infections, whereas C min monitoring would drive the timing between one and another injection, while avoiding drug toxicity. Aminoglycoside Therapeutic Drug Monitoring (TDM) was not routinely used in our study. We did not find any factors statistically associated with aminoglycoside TDM. PK data were also difficult to obtain with few patients achieving the recommended plasmatic concentration values.
Beside the high number of inadequate plasma concentration of aminoglycoside, it is interesting to note that there was little adjustment of aminoglycoside dose or interval schemes. A part of explanation may be the delay needed to obtain the PK results.
In our study, renal failure was defined by a rise of >25% of serum creatinine. There is no consensual definition of renal failure in studies on aminoglycosides. We compared with different published definitions and found that the risk factors associated in the multivariate analysis were similar. We also compared with a definition of renal failure using the classification of NKF [9] . It also had a good correlation with the results found with our definition. The two most important factors associated with the aminoglycosides renal toxicity were treatment duration (≥3 days) and concomitant use of nephrotoxic drug such ACEi or loop diuretic.
Conclusion
Aminoglycoside are commonly used in the elderly with impaired conditions and usually severe disease. When prescribing aminoglycoside, it is important to use the highest dose and the shortest as possible (<3 days). Limiting concomitant prescription of other nephrotoxic drugs could be also relevant to prevent nephrotoxicity. PK monitoring is helpful in order to adapt aminoglycoside dose and interval schemes according to the good practice recommendations, especially if the patient has renal impairment risk factors.
Key points
• Aminoglycoside are commonly used in oldest old patients with impaired conditions and usually severe disease.
• When prescribing aminoglycoside, it is important to use the right high dose for as short as possible (<3 days). • Whenever it's possible, limiting concomitant prescription of other nephrotoxic drugs could prevent aminoglycoside nephrotoxicity.
